



Centre de Santé et Services Sociaux Inuulitsivik
Inuulitsivik Health & Social Services Centre
Puvirnituq, Québec J0M 1P0
T 819 988-2957 / F 819 988-2796

ᐅᓄᓄᓄ ᐅᓄᓄᓄ ᐅᓄᓄᓄ ᐅᓄᓄᓄ
UNGAVA TULATTAVIK HEALTH CENTER
CENTRE DE SANTÉ TULATTAVIK DE L'UNGAVA

EMBOSSER ICI LA CARTE DU CSI OU CSTU,
SI NON DISPONIBLE, INSCRIRE LES NOM, PRÉNOM,
DATE DE NAISSANCE ET NUMÉRO DOSSIER
EMBOSS HERE THE CARD OF IHC OR UTHC,
IF NOT AVAILABLE, WRITE THE NAME, SURNAME,
DATE OF BIRTH AND FILE NUMBER

LATENT TB INFECTION
ADULT AND PEDIATRIC
FOLLOW-UP PROTOCOL – STANDARD MEDICAL
ORDER • INH DAILY or DOT 2x/week

Purpose: To ensure a standard process for the management of LTBI (latent TB infection) cases and the medical prescription of the necessary follow-up by the relevant health professionals.

Objectives

- a) Ensure use of the most effective prophylaxis for latent TB infection (LTBI) and in so doing, prevent the development of active TB disease.
- b) Ensure regular and optimal follow-up of people with LTBI who are undergoing treatment.
- c) Quickly identify any issues regarding compliance and offer the appropriate support.
- d) Quickly detect adverse reactions and ensure their management (*Guide TB*, Québec, 2017).

This order must be initiated by a physician at the time of the LTBI diagnosis and the prescription of TB treatment.

Notes: → To reach out to the pneumologists :

- Pediatric pneumologist, write to: MCHTB & 06CH_CUSM MCHTB@MUHC.MCGILL.CA or Zofia Zysman-Colman (Med) zofia.zysman-colman.med@ssss.gouv.qc.ca
- Adult pneumologist: Use SAFIR system : [Connect to SAFIR \(gouv.qc.ca\)](http://Connect.to.SAFIR(gouv.qc.ca))
In case SAFIR is unavailable, write to: Faiz Ahmad Khan faiz.ahmad.khan.med@ssss.gouv.qc.ca ou Richard Menzies, Dr. dick.menzies@mcgill.ca
- Pneumologist on call at the MUHC: 514 934-1934.

→ Whenever a new LTBI diagnosis is made, you must notify the Public Health TB team (NRBHSS) at tuberculose-santepublique.nrbhss@ssss.gouv.qc.ca.

Important note: All individual medical prescriptions have priority over the “Standard” follow-up described in this procedure.

Instructions regarding use of the protocol

The following order, once signed and dated by the physician, will constitute a medical prescription for the tests and paraclinical exams required to enable the follow-up of patients with LTBI. Nurses and physicians must check off and sign the boxes related to their specific tasks as soon as the prescribed actions are completed. Medication prescriptions, however, will be prepared on prescription sheets specifically for LTBI treatment.

Written by: Dr. Latoya Campbell, UTHC and Dr. Élise Bélanger-Desjardins, IHC
Dr. Jean-François Proulx and the NRBHSS infectious diseases nursing team
Dr. Faiz Ahmad Khan and Dr. David Zielinski, pneumologists and TB consultants, MUHC and Nunavik

Revised by: Dr. Latoya Campbell, UTHC and Dr. Élise Bélanger-Desjardins, IHC
Dr. Jean-François Proulx and Aurélie Heurtebize, NRBHSS
2020-10-01

Approved by: CMDPSF executive committee, IHC and UTHC, 2020-12



Centre de Santé et Services Sociaux Inuulitsivik
 Inuulitsivik Health & Social Services Centre
 Puvirnituq, Québec J0M 1P0
 T 819 988-2957 / F 819 988-2796

ᐅᓄᓄᓄ ᐅᓄᓄᓄ ᐅᓄᓄᓄ ᐅᓄᓄᓄ
 UNGAVA TULATTAVIK HEALTH CENTER
 CENTRE DE SANTÉ TULATTAVIK DE L'UNGAVA

EMBOSSER ICI LA CARTE DU CSI OU CSTU,
 SI NON DISPONIBLE, INSCRIRE LES NOM, PRÉNOM,
 DATE DE NAISSANCE ET NUMÉRO DOSSIER
 EMBOSS HERE THE CARD OF IHC OR UTHC,
 IF NOT AVAILABLE, WRITE THE NAME, SURNAME,
 DATE OF BIRTH AND FILE NUMBER

LATENT TB INFECTION
ADULT AND PEDIATRIC
FOLLOW-UP PROTOCOL – STANDARD MEDICAL
ORDER • INH DAILY or DOT 2x/week

Positive QuantiFERON-TB Gold test on: / / (if applicable)

TST result: mm **Date :** / /

Threshold values for TST and indications regarding LTBI treatment

TST	Indications regarding preventive treatment
≥ 5 mm	<input type="checkbox"/> Persons living in a priority village¹ <input type="checkbox"/> Mass screening in the event of an outbreak AND as determined by Nunavik Public Health Department. <input type="checkbox"/> Children who received the BCG vaccine less than 24 months earlier.
≥ 5 mm	<input type="checkbox"/> HIV infection. <input type="checkbox"/> Recent contact with a contagious tuberculosis case. <input type="checkbox"/> Presence of fibronodular disease on chest x-ray (healed TB, and not previously treated or treated inadequately). <input type="checkbox"/> Organ transplantation (related to immune suppressant therapy). <input type="checkbox"/> Other immunosuppressive drugs, e.g., corticosteroids (equivalent of ≥ 15 mg/day of prednisone for 1 month or more; the risk of active TB disease increases with the dose and the duration of treatment). <input type="checkbox"/> Renal failure requiring hemodialysis. <input type="checkbox"/> TNF (tumour necrosis factor) alpha inhibitor use.
≥ 10 mm	<input type="checkbox"/> Persons living in a village not deemed a priority by Nunavik Public Health Department. <input type="checkbox"/> Shift in the last 2 years with no known exposure. <input type="checkbox"/> Shift following a recent contact, regardless of the time elapsed between the 2 TST. <input type="checkbox"/> Other immunodeficiency (neck and brain cancer). <input type="checkbox"/> Silicosis. <input type="checkbox"/> People (of any age) having travelled to a country with a high rate over the past 2 years, depending on the length of stay and type of activities. <input type="checkbox"/> Users of injected drugs who are HIV-negative. • Residents and workers of health institutions or correctional facilities. • Workers in homeless shelters. • Homeless people who can be administered a preventive treatment under direct observation. <input type="checkbox"/> All other high-risk patients (persons with diabetes mellitus, who are underweight or who smoke at least one pack of cigarettes per day).

MD signature: _____ License no.: _____ Date: / /
yyyy mm dd

¹ To view the list of priority villages prepared by Public Health, see [Boîte à outils – Tuberculose](#) (English page).
 (DSPu-TB_ITL_PROT-SUIVI-INH-DIE-TOD_EN, V2024-09-06)



Centre de Santé et Services Sociaux Inuulitsivik
 Inuulitsivik Health & Social Services Centre
 Puvirnituq, Québec J0M 1P0
 T 819 988-2957 / F 819 988-2796

ᐅᓄᓄᓄ ᐅᐭᐭᐭ ᐱᐭᐭᐭᐭᐭᐭᐭᐭ
 UNGAVA TULATTAVIK HEALTH CENTER
 CENTRE DE SANTÉ TULATTAVIK DE L'UNGAVA

EMBOSSER ICI LA CARTE DU CSI OU CSTU,
 SI NON DISPONIBLE, INSCRIRE LES NOM, PRÉNOM,
 DATE DE NAISSANCE ET NUMÉRO DOSSIER
 EMBOSS HERE THE CARD OF IHC OR UTHC,
 IF NOT AVAILABLE, WRITE THE NAME, SURNAME,
 DATE OF BIRTH AND FILE NUMBER

LATENT TB INFECTION
ADULT AND PEDIATRIC
FOLLOW-UP PROTOCOL – STANDARD MEDICAL
ORDER • INH DAILY or DOT 2x/week

When	Who	Interventions and investigations	Date and signature
Prior to treatment	Doctor	<p>Before prescribing INH DAILY or DOT 2x/week:</p> <ul style="list-style-type: none"> <input type="checkbox"/> Ensure a CXR has been taken recently (< 12 weeks since the last CXR) <input type="checkbox"/> If BK tests are requested, make sure culture results are negative (unless the expert consulted stipulates otherwise) <p>Also check for:</p> <ul style="list-style-type: none"> 1. Prior active TB: <input type="checkbox"/> Yes <input type="checkbox"/> No 2. History of hepatitis following TB treatment: <input type="checkbox"/> Yes <input type="checkbox"/> No 3. Index case resistant to INH²: <input type="checkbox"/> Yes <input type="checkbox"/> No <p>Note: - IF YES (1, 2 and/or 3), reach out to the pneumologists³ - IF NO (1, 2 and 3), initiate the LTBI treatment (<i>ITL_PRESC-MED-INH-DIE_EN</i>)</p> <ul style="list-style-type: none"> <input type="checkbox"/> Check with the pharmacist to determine whether there are any interactions with other drugs <input type="checkbox"/> <u>Prescribe initial blood test:</u> <input type="checkbox"/> FSC, liver function, creat. <input type="checkbox"/> HIV⁴ (verbal consent) <input type="checkbox"/> Syphilis⁵ <input type="checkbox"/> <u>Prescribe monthly F/up blood test PRN⁶:</u> Liver function, creat. 	<p style="text-align: center;">_____ Signature</p> <p>YYYY/ MM/ DD</p>
<p>1st day/date of the onset of Tx</p> <p>___/___/___ YY/ MM/ DD</p>	Nurse	<p>Before beginning INH DAILY or DOT 2x/week:</p> <ul style="list-style-type: none"> <input type="checkbox"/> Make sure there are no active TB disease symptoms. In the presence of any such symptoms, request a medical opinion STAT before initiating treatment. <input type="checkbox"/> Make sure to have injectable pyridoxine on hand in case of INH intoxication <input type="checkbox"/> Initiate INH and pyridoxine according to the medical prescription (DAILY or DOT) <input type="checkbox"/> Educate the patient (treatment, compliance, side effects) <input type="checkbox"/> Prepare to complete follow-up forms: <ul style="list-style-type: none"> <input type="checkbox"/> Registration of the medication (<i>ITL-ENREG-MED-INH-DIE_EN</i> or <i>TOD_EN</i>) <input type="checkbox"/> Compliance curve if INH DIE⁷ (<i>ITL_COURBE-INH-DIE_EN</i>) <input type="checkbox"/> Monthly clinical assessment (<i>TB-ACT-ITL_EVAL-CLIN-MENS_EN</i>) <input type="checkbox"/> As per medical prescription above, take initial blood test: FSC, liver function, creat., HIV⁴, syphilis⁵ 	<p style="text-align: center;">_____ Signature</p> <p>YYYY/ MM/ DD</p>

MD signature: _____ License no.: _____ Date: ____/____/____

² If the antibiogram of the index case is unknown when prescribing the preventive treatment, make sure to adjust the user's plan as soon as any resistance to the prescribed TB treatment is confirmed.

³ Contact information for pneumologists is provided on page 1 of this document.

⁴ HIV is a major risk factor for the progression of latent tuberculosis infection to active tuberculosis.

⁵ Offer opportunistic screening for syphilis to people aged 14 years or more.

⁶ **Child**: If symptomatic or abnormal results initial blood test.

Adult: If symptomatic **OR** ≥ 50 years old **OR** in the presence of one of the following conditions: Pregnancy or childbirth over the past 3 months, progressive cirrhosis or progressive chronic hepatitis, all causes combined, hepatitis C, hepatitis B with abnormal concentrations of transmines, daily alcohol consumption, intake of other hepatotoxic medications, history of hepatitis provoked by medications. (*Guide d'intervention – La tuberculose*, MSSS, 2017)

⁷ The compliance curve is not used in TOD, seeing as every dose administered/taken is registered.

(DSPu-TB_ITL_PROT-SUIVI-INH-DIE-TOD_EN, V2024-09-06)



Centre de Santé et Services Sociaux Inuułitsivik
Inuułitsivik Health & Social Services Centre

Puvivrituaq, Québec J0M 1P0
T 819 988-2957 / F 819 988-2796

ᐅᓃᓃᓃ ᐅᓃᓃᓃ ᐅᓃᓃᓃ ᐅᓃᓃᓃ
UNGAVA TULATTAVIK HEALTH CENTER
CENTRE DE SANTÉ TULATTAVIK DE L'UNGAVA

EMBOSSER ICI LA CARTE DU CSI OU CSTU,
SI NON DISPONIBLE, INSCRIRE LES NOM, PRÉNOM,
DATE DE NAISSANCE ET NUMÉRO DOSSIER
EMBOSS HERE THE CARD OF IHC OR UTHC,
IF NOT AVAILABLE, WRITE THE NAME, SURNAME,
DATE OF BIRTH AND FILE NUMBER

LATENT TB INFECTION
ADULT AND PEDIATRIC
FOLLOW-UP PROTOCOL – STANDARD MEDICAL
ORDER • INH DAILY or DOT 2x/week

When	Who	Interventions and investigations	Date and signature
End of 1 st month of Tx ____/____/____ YY/ MM/ DD	Nurse	<input type="checkbox"/> Regular monthly follow-up: Notify the physician if abnormal <input type="checkbox"/> Medication follow-up and support to the patient (<i>ITL-ENREG-MED-INH-DIE_EN</i> or <i>TOD_EN</i>) and (<i>ITL_COURBE-INH-DIE_EN</i>) if INH DIE? <input type="checkbox"/> Monthly clinical assessment (<i>TB-ACT-ITL_EVAL-CLIN-MENS_EN</i>) <input type="checkbox"/> As per medical prescription, take monthly F/up blood test PRN: liver function, creat.	_____ Signature YYYY/ MM/ DD
End of 2 nd month of Tx ____/____/____ YY/ MM/ DD	Nurse	<input type="checkbox"/> Regular monthly follow-up: Notify the physician if abnormal. <input type="checkbox"/> Medication follow-up and support to the patient (<i>ITL-ENREG-MED-INH-DIE_EN</i> or <i>TOD_EN</i>) and (<i>ITL_COURBE-INH-DIE_EN</i>) if INH DIE? <input type="checkbox"/> Monthly clinical assessment (<i>TB-ACT-ITL_EVAL-CLIN-MENS_EN</i>) <input type="checkbox"/> As per medical prescription, take monthly F/up blood test PRN: liver function, creat.	_____ Signature YYYY/ MM/ DD
End of 3 rd month of Tx ____/____/____ YY/ MM/ DD	Nurse	<input type="checkbox"/> Regular monthly follow-up: Notify the physician if abnormal. <input type="checkbox"/> Medication follow-up and support to the patient (<i>ITL-ENREG-MED-INH-DIE_EN</i> or <i>TOD_EN</i>) and (<i>ITL_COURBE-INH-DIE_EN</i>) if INH DIE? <input type="checkbox"/> Monthly clinical assessment (<i>TB-ACT-ITL_EVAL-CLIN-MENS_EN</i>) <input type="checkbox"/> As per medical prescription, take monthly F/up blood test PRN: liver function, creat.	_____ Signature YYYY/ MM/ DD
End of 4 th month of Tx ____/____/____ YY/ MM/ DD	Nurse	<input type="checkbox"/> Regular monthly follow-up: Notify the physician if abnormal. <input type="checkbox"/> Medication follow-up and support to the patient (<i>ITL-ENREG-MED-INH-DIE_EN</i> or <i>TOD_EN</i>) and (<i>ITL_COURBE-INH-DIE_EN</i>) if INH DIE? <input type="checkbox"/> Monthly clinical assessment (<i>TB-ACT-ITL_EVAL-CLIN-MENS_EN</i>) <input type="checkbox"/> As per medical prescription, take monthly F/up blood test PRN: liver function, creat.	_____ Signature YYYY/ MM/ DD
End of 5 th month of Tx ____/____/____ YY/ MM/ DD	Nurse	<input type="checkbox"/> Regular monthly follow-up: Notify the physician if abnormal. <input type="checkbox"/> Medication follow-up and support to the patient (<i>ITL-ENREG-MED-INH-DIE_EN</i> or <i>TOD_EN</i>) and (<i>ITL_COURBE-INH-DIE_EN</i>) if INH DIE? <input type="checkbox"/> Monthly clinical assessment (<i>TB-ACT-ITL_EVAL-CLIN-MENS_EN</i>) <input type="checkbox"/> As per medical prescription, take monthly F/up blood test PRN: liver function, creat.	_____ Signature YYYY/ MM/ DD
End of 6 th month of Tx ____/____/____ YY/ MM/ DD	Nurse	<input type="checkbox"/> Regular monthly follow-up: Notify the physician if abnormal. <input type="checkbox"/> Medication follow-up and support to the patient (<i>ITL-ENREG-MED-INH-DIE_EN</i> or <i>TOD_EN</i>) and (<i>ITL_COURBE-INH-DIE_EN</i>) if INH DIE? <input type="checkbox"/> Monthly clinical assessment (<i>TB-ACT-ITL_EVAL-CLIN-MENS_EN</i>) <input type="checkbox"/> As per medical prescription, take monthly F/up blood test PRN: liver function, creat.	_____ Signature YYYY/ MM/ DD

MD signature: _____ License no.: _____ Date: / /



Centre de Santé et Services Sociaux Inuulitsivik
Inuulitsivik Health & Social Services Centre
Puvirnituq, Québec J0M 1P0
T 819 988-2957 / F 819 988-2796

ᐅᓴᓴᓴ ᐅᓴᓴᓴ ᐅᓴᓴᓴ ᐅᓴᓴᓴ
UNGAVA TULATTAVIK HEALTH CENTER
CENTRE DE SANTÉ TULATTAVIK DE L'UNGAVA

EMBOSSER ICI LA CARTE DU CSI OU CSTU,
SI NON DISPONIBLE, INSCRIRE LES NOM, PRÉNOM,
DATE DE NAISSANCE ET NUMÉRO DOSSIER
EMBOSS HERE THE CARD OF IHC OR UTHC,
IF NOT AVAILABLE, WRITE THE NAME, SURNAME,
DATE OF BIRTH AND FILE NUMBER

LATENT TB INFECTION
ADULT AND PEDIATRIC
FOLLOW-UP PROTOCOL – STANDARD MEDICAL
ORDER • INH DAILY or DOT 2x/week

When	Who	Interventions and investigations	Date and signature
End of 7 th month of Tx ____/____/____ YY/ MM/ DD	Nurse	<input type="checkbox"/> Regular monthly follow-up: Notify the physician if abnormal. <input type="checkbox"/> Medication follow-up and support to the patient (<i>ITL-ENREG-MED-INH-DIE_EN</i> or <i>TOD_EN</i>) and (<i>ITL_COURBE-INH-DIE_EN</i>) if INH DIE? <input type="checkbox"/> Monthly clinical assessment (<i>TB-ACT-ITL_EVAL-CLIN-MENS_EN</i>) <input type="checkbox"/> As per medical prescription, take monthly F/up blood test PRN: liver function, creat.	_____ Signature YYYY/ MM/ DD
End of 8 th month of Tx ____/____/____ YY/ MM/ DD	Nurse	<input type="checkbox"/> Regular monthly follow-up: Notify the physician if abnormal. <input type="checkbox"/> Medication follow-up and support to the patient (<i>ITL-ENREG-MED-INH-DIE_EN</i> or <i>TOD_EN</i>) and (<i>ITL_COURBE-INH-DIE_EN</i>) if INH DIE? <input type="checkbox"/> Monthly clinical assessment (<i>TB-ACT-ITL_EVAL-CLIN-MENS_EN</i>) <input type="checkbox"/> As per medical prescription, take monthly F/up blood test PRN: liver function, creat.	_____ Signature YYYY/ MM/ DD
End of the Tx 9 th month ____/____/____ YY/ MM/ DD	Doctor	<input type="checkbox"/> Document compliance and end of the treatment <input type="checkbox"/> Complete and sign the post-treatment <i>Clinical and radiological follow-up guide</i> (<i>TB-ACT-ITL_GUIDE-SCR_EN</i>) <input type="checkbox"/> Update the list of problems (prior history) in the patient record	_____ Signature YYYY/ MM/ DD
	Nurse	<input type="checkbox"/> Regular monthly follow-up: Notify the physician if abnormal. <input type="checkbox"/> Medication follow-up and support to the patient (<i>ITL-ENREG-MED-INH-DIE_EN</i> or <i>TOD_EN</i>) and (<i>ITL_COURBE-INH-DIE_EN</i>) if INH DIE? <input type="checkbox"/> Monthly clinical assessment (<i>TB-ACT-ITL_EVAL-CLIN-MENS_EN</i>) <input type="checkbox"/> Plan for clinical and radiological follow-up as required (<i>TB-ACT-ITL_GUIDE-SCR_EN</i>) <input type="checkbox"/> Send all completed documents to Public Health Department	_____ Signature YYYY/ MM/ DD

MD signature: _____ License no.: _____ Date: / /



Centre de Santé et Services Sociaux Inuulitsivik
 Inuulitsivik Health & Social Services Centre
 Puvirnituq, Québec J0M 1P0
 T 819 988-2957 / F 819 988-2796

ᐅᓄᓄᓄ ᐅᓄᓄᓄ ᐅᓄᓄᓄᓄᓄᓄᓄᓄ
 UNGAVA TULATTAVIK HEALTH CENTER
 CENTRE DE SANTÉ TULATTAVIK DE L'UNGAVA

EMBOSSER ICI LA CARTE DU CSI OU CSTU,
 SI NON DISPONIBLE, INSCRIRE LES NOM, PRÉNOM,
 DATE DE NAISSANCE ET NUMÉRO DOSSIER
 EMBOSS HERE THE CARD OF IHC OR UTHC,
 IF NOT AVAILABLE, WRITE THE NAME, SURNAME,
 DATE OF BIRTH AND FILE NUMBER

LATENT TB INFECTION
ADULT AND PEDIATRIC
FOLLOW-UP PROTOCOL – STANDARD MEDICAL
ORDER • INH DAILY or DOT 2x/week

Extension of the planned duration of the treatment: To use if the treatment extends beyond 9 months. • Apply the interventions from the line *End of the treatment* for the month during which the treatment will be completed. • Beyond 12 months, preventive treatment is considered inadequate.

When	Who	Interventions and investigations	Date and signature
End of 10 th month of Tx / / YY / MM / DD	Nurse	<input type="checkbox"/> Regular monthly follow-up: Notify the physician if abnormal. <input type="checkbox"/> Medication follow-up and support to the patient (<i>ITL-ENREG-MED-INH-DIE_EN</i> or <i>TOD_EN</i>) and (<i>ITL_COURBE-INH-DIE_EN</i>) if INH DIE? <input type="checkbox"/> Monthly clinical assessment (<i>TB-ACT-ITL_EVAL-CLIN-MENS_EN</i>) <input type="checkbox"/> As per medical prescription, take monthly F/up blood test PRN: liver function, creat.	_____ Signature YYYY / MM / DD
End of 11 th month of Tx / / YY / MM / DD		<input type="checkbox"/> Regular monthly follow-up: Notify the physician if abnormal. <input type="checkbox"/> Medication follow-up and support to the patient (<i>ITL-ENREG-MED-INH-DIE_EN</i> or <i>TOD_EN</i>) and (<i>ITL_COURBE-INH-DIE_EN</i>) if INH DIE? <input type="checkbox"/> Monthly clinical assessment (<i>TB-ACT-ITL_EVAL-CLIN-MENS_EN</i>) <input type="checkbox"/> As per medical prescription, take monthly F/up blood test PRN: liver function, creat.	_____ Signature YYYY / MM / DD
End of Tx 12 th month / / YY / MM / DD	Doctor	<input type="checkbox"/> Document compliance and end of the treatment <input type="checkbox"/> Complete and sign the post-treatment <i>Clinical and radiological follow-up guide</i> (<i>TB-ACT-ITL_GUIDE-SCR_EN</i>) <input type="checkbox"/> Update the list of problems (prior history) in the patient record	_____ Signature YYYY / MM / DD
	Nurse	<input type="checkbox"/> Regular monthly follow-up: Notify the physician if abnormal. <input type="checkbox"/> Medication follow-up and support to the patient (<i>ITL-ENREG-MED-INH-DIE_EN</i> or <i>TOD_EN</i>) and (<i>ITL_COURBE-INH-DIE_EN</i>) if INH DIE? <input type="checkbox"/> Monthly clinical assessment (<i>TB-ACT-ITL_EVAL-CLIN-MENS_EN</i>) <input type="checkbox"/> Plan for clinical and radiological follow-up as required (<i>TB-ACT-ITL_GUIDE-SCR_EN</i>) <input type="checkbox"/> Send all completed documents to Public Health Department	_____ Signature YYYY / MM / DD

MD signature: _____ License no.: _____ Date: yyyy / mm / dd